This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Granulocyte colony stimulating factors

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Granulocyte colony stimulating factors are naturally occurring cytokines which increase the rate of maturation of granulocytes within the bone marrow. They were developed for limited clinical use on the assumption that reducing the severity and duration of the neutropaenia - for example after the administration of chemotherapy - will decrease the risks of infection.

In practice, G-CSF does improve the neutrophil count and may have a role in the management of neutropenia induced by cytotoxic chemotherapy. GM-CSF increases monocytes, eosinophils and neutrophils. There is some evidence that GM-CSF may increase the antibody-dependent cytolysis of some tumour cells.

Other areas of potential use without proven benefit as yet:

  • aplastic anaemia
  • myelodysplasia
  • AIDS

Side effects of GM-CSF, less so with G-CSF, include:

  • lethargy
  • bone pain
  • myalgia
  • anorexia
  • erythema at injection site
  • fever
  • increased serum alkaline phosphatase and lactic dehydrogenase

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.